glp 1 agonists adverse effects Relative of glucagon-like peptide-1 (GLP-1) vs Semaglutide side effects for diabetes
Description
Best Pract Res Clin Endocrinol Metab 23(4):443452
Increased competition maybe better prices
The FDA declared the semaglutide shortage resolved on February 21, 2025, and the tirzepatide shortage resolved in late 2024
The neuroprotective effect of GLP-1R agonism is similar to that conferred by nerve growth factor (NGF) and is blocked when PC12 cells are co-incubated with exendin (939) [825]
However, early human evidence for cocaine use disorder remains limited and mixed
